STOCK TITAN
  1. Home
  2. News
  3. AMRN

Amarin Corp - AMRN STOCK NEWS

Welcome to our dedicated news page for Amarin (Ticker: AMRN), a resource for investors and traders seeking the latest updates and insights on Amarin.

Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect Amarin's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.

Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of Amarin's position in the market.

News
Amarin Applauds HealthyWomen’s Citizen’s Petition Urging FDA To Take Further Action On Fenofibrate Prescribing in Patients at Risk of Cardiovascular Event
Rhea-AI Summary
Amarin supports a petition urging the FDA to address off-label prescribing of fenofibrates, highlighting the lack of clinical benefits in reducing cardiovascular disease. Despite FDA label changes in 2015, over 11 million prescriptions were written in 2023, exposing patients to unnecessary risks and payors to increased costs.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.53%
Tags
none
-
News
Amarin Announces Results of Annual General Meeting of Shareholders
Rhea-AI Summary
Amarin plc (NASDAQ:AMRN) announces shareholder approval for a $50 million share repurchase program at its 2024 Annual General Meeting. The Company can now proceed with the program pending U.K. High Court approval, along with other resolutions passed, including re-election of directors and approval of executive compensation.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.74%
Tags
none
-
News
Amarin to Report First Quarter 2024 Financial Results and Host Conference Call on May 1, 2024
Rhea-AI Summary
Amarin plc (AMRN) will host a conference call on May 1, 2024, to discuss its first quarter 2024 financial results. Shareholders can submit questions through Say Technologies. Access to the live call and replay details are provided.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-3.87%
Tags
conferences earnings
News
Amarin Highlights Key Data Providing Mechanistic Insights into Eicosapentaenoic Acid (EPA) at ACC.24
Rhea-AI Summary
Amarin plc (AMRN) highlighted three data presentations at ACC.24 showcasing the mechanistic activity of Eicosapentaenoic acid (EPA), emphasizing its effects on endothelial cell dysfunction and oxidation of samples enriched with Lp(a). The studies further the understanding of VASCEPA/VAZKEPA's mechanism of action in reducing cardiovascular events.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.9%
Tags
none
-
News
New REDUCE-IT® Analyses Show VASCEPA®/VAZKEPA® (Icosapent Ethyl) Benefit in High-Risk Cardiovascular Disease Patient Subgroups
Rhea-AI Summary
Amarin plc presented findings on VASCEPA/VAZKEPA utility in REDUCE-IT patient subgroups based on baseline high/low Lp(a) and LDL-C levels. The data highlighted the significant impact of VASCEPA/VAZKEPA in reducing MACE and lowering cardiovascular events, regardless of baseline LDL-C levels. The Lp(a) analysis results were published in the Journal of the American College of Cardiology (JACC), reinforcing the positive outcomes of the study.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
none
-
News
Amarin Provides Update on VAZKEPA® (Icosapent Ethyl) Intellectual Property Portfolio in Europe
Rhea-AI Summary
Amarin plc (NASDAQ:AMRN) has received a Decision to Grant from the European Patent Office (EPO) for a new patent extending VAZKEPA exclusivity in Europe until 2039. This extends the commercial runway for VAZKEPA by eight additional years, reinforcing the Company's IP rights and strengthening its position in the European market.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
7.07%
Tags
none
News
Research Evaluating Benefits of VASCEPA®/VAZKEPA® (icosapent ethyl) to be Presented at the American College of Cardiology’s (ACC) Annual Scientific Session & Expo
Rhea-AI Summary
Amarin plc (AMRN) announced additional patient subgroup analyses from the REDUCE-IT outcomes trial and mechanistic data on icosapent ethyl (IPE)/eicosapentaenoic acid (EPA) to be presented at the American College of Cardiology's Annual Scientific Session. The data supports VASCEPA/VAZKEPA's efficacy in reducing cardiovascular events across different patient subgroups, regardless of baseline Lipoprotein(a) or LDL-C levels.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.84%
Tags
none
-
News
Amarin Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update
Rhea-AI Summary
Amarin Corporation plc (AMRN) reports total revenues of $75 million in Q4 and $306 million for full-year 2023. They reaffirm a year-end cash position of $321 million and a positive cash flow of $10 million for 2023. The company plans to execute a share repurchase program of up to $50 million by Q2 2024. Despite a decrease in net product revenue, Amarin remains focused on building momentum in 2024 and beyond.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-18.94%
Tags
earnings
-
News
Amarin to Report Fourth Quarter and Full Year 2023 Financial Results and Host Conference on February 29, 2024
Rhea-AI Summary
Amarin Corporation plc (AMRN) will host a conference call to discuss its fourth quarter and year-end 2023 results on February 29th, 2024. The call will include a Q&A session and highlights from 2023. Shareholders can submit questions through Say Technologies for the earnings call.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
3.39%
Tags
conferences earnings
News
Amarin Chairman & CEO Issue Letter to Shareholders
Rhea-AI Summary
Amarin Corporation plc (NASDAQ:AMRN) announced a letter to shareholders highlighting significant actions taken to strengthen the company, including leadership restructuring, operational improvements, and financial discipline. The company's focus on extending market leadership in the U.S., accelerating revenues in Europe, and advancing market access in the Rest of World (RoW) positions it for shareholder value in 2024 and beyond.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
9.52%
Tags
none
Stock AMRN logo
Amarin Corp

Nasdaq:AMRN

AMRN Rankings

#3282 Ranked by Market Cap
#4474 Ranked by Stock Gains
N/A Ranked by Dividends

AMRN Stock Data

359.57M
383.11M
1.54%
23.81%
4.49%
Pharmaceutical Preparation Manufacturing
Manufacturing
Link
Ireland
First Floor Block 3 The Oval

About AMRN

amarin corporation plc is a biopharmaceutical company focused on the commercialization and development of therapeutics to improve cardiovascular health. amarin's product development program leverages its extensive experience in lipid science and the potential therapeutic benefits of polyunsaturated fatty acids. vascepa® (icosapent ethyl) is amarin's first fda approved product and is available in the united states by prescription. for more information about vascepa visit www.vascepa.com.